Read Summary

  1. Ndiya Ogba, PhD28,*
  1. From 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 2Moffitt Cancer Center; 3Massachusetts General Hospital Cancer Center; 4UC San Diego Moores Cancer Center; 5Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; 6City of Hope Comprehensive Cancer Center; 7Fox Chase Cancer Center; 8Huntsman Cancer Institute at the University of Utah; 9University of Alabama at Birmingham Comprehensive Cancer Center; 10University of Michigan Comprehensive Cancer Center; 11University of Washington/Seattle Cancer Care Alliance; 12Fred & Pamela Buffett Cancer Center; 13Stanford Comprehensive Cancer Center; 14UCSF Helen Diller Family Comprehensive Cancer Center; 15Dana-Farber/Brigham and Women’s Cancer Center; 16Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 17Vanderbilt-Ingram Cancer Center; 18The University of Texas MD Anderson Cancer Center; 19The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; 20Yale Cancer Center/Smilow Cancer Hospital; 21Mayo Clinic Cancer Center; 22University of Colorado Cancer Center; 23University of Wisconsin Carbone Cancer Center; 24Memorial Sloan Kettering Cancer Center; 25St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; 26Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 27Roswell Park Cancer Institute; and 28National Comprehensive Cancer Network.


The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel’s discussion and underlying data supporting the most recent recommendations for R/R ALL management.

Print Friendly, PDF & Email